Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

121.47 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
News headline image
Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today ↗
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.25% on an annualized basis producing an average annual return of 17.44%. Currently, Incyte has a market capitalization of... 
Via Benzinga
News headline image
2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
News headline image
3 Market-Beating Stocks with Competitive Advantages
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup ↗
Via Chartmill
News headline image
2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
Incyte (NASDAQ:INCY) Passes Minervini Trend and High-Growth Screens, But Setup Demands Patience ↗
Via Chartmill
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup ↗
Via Chartmill
Incyte (NASDAQ:INCY): High Growth Stock Slides on Q2 Beat but Steep Guidance Cut ↗
Via Chartmill
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years ↗
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of... 
Via Benzinga
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte Corporation
Via Business Wire
News headline image
1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
Topics Supply Chain
INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings ↗
Via Chartmill
INCYTE CORP (NASDAQ:INCY) Screens as a High Growth Momentum Stock with a Breakout Setup ↗
Via Chartmill
Incyte Corp (NASDAQ:INCY) Shows Value Stock Strength With Strong Fundamentals and Low Valuation ↗
Via Chartmill
News headline image
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
From Incyte
Via Business Wire
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below. ↗
Via Chartmill
News headline image
Incyte Q2 Earnings Call Highlights ↗
Incyte (NASDAQ:INCY) reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash... 
Via MarketBeat
Topics Earnings
News headline image
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on ... 
Via StockStory
News headline image
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Incyte
Via Business Wire
News headline image
What To Expect From Incyte’s (INCY) Q2 Earnings
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for. Incyte beat analy... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
From Incyte
Via Business Wire
News headline image
Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?
Incyte has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 8.6% to $114.25 per... 
Via StockStory
Topics Stocks
News headline image
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
From Incyte
Via Business Wire
News headline image
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings. 
Via The Motley Fool
News headline image
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
News headline image
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
From Incyte
Via Business Wire
News headline image
1 Mid-Cap Stock to Research Further and 2 We Avoid
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.